Gain Therapeutics Inc
GANX
Company Profile
Business description
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
Contact
4800 Montgomery Lane
Suite 220
BethesdaMD20814
USAT: +1 301 500-1556
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
21
Stocks News & Analysis
stocks
Chip stock selloff deepens in Asia, extends to Europe and US
The week’s tech stock rout continues despite strong earnings from TSMC and ASML.
stocks
Downgrade for ASX listed fund manager as redemptions pile on
Persistent outflows erode earnings outlook.
stocks
Tesla stock is down nearly 20% this year. Is it a buy ahead of earnings?
Following the rollout of its first autonomous Cybercab, here’s what we expect from Tesla’s earnings report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,940.40 | 100.00 | 1.13% |
| CAC 40 | 7,962.19 | 27.49 | 0.35% |
| DAX 40 | 25,624.93 | 242.31 | 0.95% |
| Dow JONES (US) | 52,177.69 | 556.21 | 1.08% |
| FTSE 100 | 10,846.87 | 6.52 | 0.06% |
| HKSE | 24,186.83 | 124.11 | 0.52% |
| NASDAQ | 26,713.03 | 20.16 | 0.08% |
| Nikkei 225 | 65,324.29 | 898.34 | 1.39% |
| NZX 50 Index | 13,753.73 | 79.07 | -0.57% |
| S&P 500 | 7,744.06 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,806.70 | 87.00 | 1.00% |
| SSE Composite Index | 3,716.28 | 8.81 | 0.24% |